Article Text

Download PDFPDF

Fibrinolytic treatment for recurrent left sided prosthetic valve thrombosis
  1. R P Balasundaram,
  2. G Karthikeyan,
  3. S S Kothari,
  4. K K Talwar,
  5. P Venugopal
  1. All India Institute of Medical Sciences, New Delhi, India
  1. Correspondence to:
    Dr Ganesan Karthikeyan
    Room 22, Cardiothoracic Sciences Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

About 20–25% of patients develop recurrent thrombosis after successful thrombolysis for a first episode of prosthetic valve thrombosis (PVT).1,2 Whereas fibrinolytic treatment (FT) is an acceptable modality of treatment for a first episode of PVT, there are few data on patients with recurrent PVT. We compared the outcome of FT in patients with recurrent PVT with those treated for a first episode.


From January 2000 to January 2003, 51 patients with 75 episodes of PVT were treated with FT. Of the 51 patients, 17 received treatment for a recurrent episode while the rest were treated for a first episode. Fifteen of the 17 patients treated for a recurrent episode had their first episode of PVT during the study period. In all, there were 26 episodes of recurrent PVT and 49 first episodes. Streptokinase was used in 59 episodes (46 first and three recurrent), and urokinase in 16 episodes (three first and 13 recurrent). Serial transthoracic echocardiography (TTE) and fluoroscopic assessment were used to guide treatment.

A protocol of prolonged fibrinolytic infusion was used. Streptokinase was given in a 250 000 U bolus over 30 minutes, followed by an infusion of 100 000 U/h. Urokinase was given in a dose of 4400 U/kg per hour as a continuous infusion.3 Throughout the duration of the infusion patients were closely monitored in an intensive care set up. Bedside TTE with Doppler imaging was carried out at the beginning of the infusion and at six hourly intervals. Leaflet mobility, the presence and extent of regurgitation, and transvalvar gradients were measured. The mean diastolic gradient (MDG) and end diastolic gradient (EDG) were measured for the mitral prostheses and the instantaneous peak to peak gradient (IPPG) for the aortic prosthesis. The mitral valve area was calculated by the pressure half time method. Cinefluoroscopy at 25 frames per second was carried out at the beginning of infusion and at 8–12 hourly intervals. The degree of restriction of disc movement and opening and closing angles were noted during each study. The indicators to terminate the infusion were: (1) improvement in clinical status accompanied by objective evidence of complete recovery on TTE and cinefluoroscopy; (2) occurrence of intracranial bleed or other major haemorrhage needing blood transfusion; (3) the elapsing of 72–96 hours even in the absence of a complete response. Patients were classified into four groups based on clinical presentation as described previously.3

The effect of FT was evaluated as haemodynamic and clinical end points. Complete haemodynamic response was defined as: (1) normalisation of transvalvar gradients on TTE (MDG ⩽ 6 mm Hg, EDG ⩽ 2 mm Hg, IPPG ⩽ 30 mm Hg), and (2) restoration of normal leaflet motion on cinefluoroscopy. Partial haemodynamic response was defined as: (1) reduction of transvalvar gradients by more than 50% from the baseline although the status before PVT was not reached; or (2) restricted movement of prosthetic valve leaflets on cinefluoroscopy even though the transvalvar gradients completely normalised. Haemodynamic failure was defined as a less than 50% decrease in the transvalvar gradients.

Complete clinical success was defined as complete haemodynamic response in the absence of any major complications. Partial clinical response was defined as either partial or complete haemodynamic response in the event of either major haemorrhagic or embolic complication (a major embolic complication was defined as one resulting in irreversible neurological damage, myocardial infarction, or needing limb salvage surgery). Clinical failure occurred in the event of haemodynamic failure or if a complication resulted in death irrespective of the haemodynamic response.

Categorical data were compared using the χ2 test. The paired t test was used to compare continuous variables between the first and recurrent episodes of PVT. A probability value of p < 0.05 was considered significant.


Demographic characteristics of patients presenting with a first PVT were similar to those with recurrent PVT. All episodes of recurrent PVT presented with haemodynamic symptoms (group 3), whereas group 1 (asymptomatic) or group 2 (systemic embolisation) symptom presentations were seen in 12% of patients during the first episode of PVT (p  =  0.02 for difference). More patients with tilting disc prostheses had recurrent PVT (23.5% v 14.7%; p  =  not significant). There was no difference in the duration of fibrinolytic infusion between the first and recurrent episodes.

Both complete haemodynamic and complete clinical response occurred less often in patients with recurrent PVT than in those with first episodes. However, these differences were not significant. Stroke and a composite of death, stroke, or major bleeding occurred more often during treatment of recurrent PVT than during first episodes of PVT (table 1). Of the 33 patients who had a complete clinical response after treatment for a first episode of PVT, 15 (45.5%) had a recurrence during the study period. Of the 17 patients with recurrent PVT, only six patients (35.3%) remained free of further episodes at the end of the study period.

Table 1

 Comparison of the results of FT for first and recurrent episodes of PVT


FT for a recurrent episode of PVT is not as efficacious as it is for the first episode and causes more adverse events. These patients have a greater tendency for repeated PVT after FT than when managed by thrombectomy (8%) or valve replacement (3%). It is possible that FT does not completely remove all of the thrombus from the valve, resulting in persistent abnormal flow patterns acting as a substrate for subsequent thromboses. Current methods of assessing restoration of valve function might not be sensitive enough to detect these minor residues. The accelerated formation of pannus on valves treated by FT may be another explanation for their predilection to recurrent PVT. This appears unlikely as most of our patients had short duration of symptoms before presentation (median 5 days, range 2–14 days) which did not differ from first episodes. Previous data suggest that duration of symptoms at presentation of less than one month favours thrombosis rather than pannus formation.4 Increased thrombus load in these predisposed valves might also explain the higher embolic stroke rate with FT in these patients.

In conclusion, recurrent episodes of PVT should probably be treated surgically.


View Abstract